The maximum recommended dose for extradural infusions of bupivacaine in children older than 1 month is 0.5 mg kg 91 h 91 but there are few specific reports of the associated blood concentrations during infusions in babies. Toxic symptoms can occur in children at plasma concentrations of bupivacaine as low as 2 g ml
. We attempted to measure venous plasma concentrations of total and free bupivacaine in babies aged 3-12 months during extradural infusions given at a rate commonly used in our hospital. We studied eight babies (mean age 33 weeks; mean weight 7.8 kg). After a mean initial dose of 1. Blood was obtained at 4, 8, 16 , 24, 32 and 40 h after starting the infusion and plasma separated by centrifugation. Total plasma bupivacaine concentration was measured using high pressure liquid chromatography (HPLC). Plasma concentrations of total bupivacaine were mostly less than 2 g ml
91
. One baby had a concentration of 2.02 g ml 91 at 32 h and showed clear evidence of accumulation of bupivacaine. Babies can accumulate bupivacaine and achieve plasma concentrations above the threshold for toxic side effects, despite infusion rates below the currently accepted maximum. The sample size in our study was small but we believe an extradural infusion rate of 0.375 mg kg The maximum recommended rate for extradural infusion of bupivacaine in children older than 1 month is 0.5 mg kg 91 h
. 1 At the time of this editorial there were no specific reports of blood concentrations of bupivacaine during extradural infusions in babies younger than 12 months. The aim of our study was to measure venous plasma concentrations of both total and free bupivacaine during continuous extradural infusion of bupivacaine 0.375 mg kg 91 h 91 for the duration of the infusion in babies aged 3-12 months.
Patients and methods
After obtaining Ethics Committee approval and informed consent from parents, we studied babies, aged 3-12 months, ASA I or II, undergoing major abdominal operations. We excluded babies born before 35 weeks' gestation.
General anaesthesia was induced using a volatile agent or propofol, and neuromuscular block was produced with atracurium or vecuronium. After intubation of the trachea the lungs were ventilated to a normal end-tidal carbon dioxide concentration with oxygen, nitrous oxide and a volatile agent. We then inserted a 23-gauge lumbar extradural catheter using a 19-gauge Tuohy needle (Portex Minipack System) and injected bupivacaine 1.25 mg kg 91 (0.25% or 0.5%). Another two doses of 0.6 mg kg 91 were given if indicated by changes in heart rate or arterial pressure, up to a maximum total dose during surgery of 2.5 mg kg
91
. Continuous infusion of 0.25% bupivacaine 0.375 mg kg 91 h 91 (equivalent to 0.15 ml kg 91 h
) was then started for postoperative pain relief. No other analgesics were given during anaesthesia.
A second cannula was inserted into a peripheral vein during anaesthesia for later collection of blood samples and flushed with heparinized saline 10 u. ml 91 . After surgery the babies were monitored with an apnoea alarm and pulse oximeter. Assessments by nursing staff of pain and sedation using four-point scoring systems and measurements of heart rate and ventilatory frequency were recorded every hour. Pain was assessed as nil, mild, moderate or severe. Sedation was assessed as awake and alert, occasionally drowsy but easy to arouse, drowsy most of the time but easy to arouse, or somnolent and difficult to arouse.
Approximately 2 ml of blood were obtained from the venous sampling cannula at 4, 8, 16, 24, 32 and 40 h after starting the continuous extradural infusion as long as the extradural infusion was running and the sampling cannula remained patent. Plasma was removed by centrifugation, frozen immediately and stored at 920 ЊC. Total bupivacaine was assayed using a modification of a high pressure liquid chromatography (HPLC) method described for measurement of lignocaine and its metabolites. 2 The sensitivity of the assay was dependent on the volume of plasma and was approximately 0.1 g ml 91 for 100 l and 0.02 g ml 91 for 500 l. The coefficient of variation was 5%.
Results
We studied eight babies. Mean age was 33 weeks (range 18-48 weeks) and mean weight 7.8 (5.6-9. The extradural infusion had seemed adequate during surgery but after operation the baby was intermittently distressed. This was attributed to colic and was treated with an infusion of morphine. The other seven babies had renal or ureteric surgery. Their hourly pain scores were nearly all assessed as "no pain" and no score was higher than "mild pain". All babies were either "awake and alert" or "drowsy but easy to arouse" for the duration of the infusion, except for one who was difficult to arouse at the first assessment after returning to the ward. There was no clinical evidence of central nervous system toxicity in any baby.
The results for total bupivacaine plasma concentrations sampled from a peripheral vein are shown in table 2 and figure 1. Most concentrations were less than 2 g ml 91 but one baby had a concentration of 2.02 g ml 91 at 32 h. The same baby showed clear evidence of accumulation of bupivacaine throughout the extradural infusion.
We attempted to separate the free fraction of bupivacaine with a micro-partition system (Amicon) and measure its plasma concentration using HPLC. In most samples the volume of plasma obtained was insufficient for the separation method or the concentration of the free drug was below the sensitivity of the assay for the volumes of plasma available (approximately 0.1 g ml 91 for 100 l).
Discussion
Extradural analgesia for postoperative pain control has become a more common technique in paediatric anaesthesia since the introduction of equipment specifically designed for use in babies and children. [3] [4] [5] [6] Plasma concentrations of local anaesthetics during continuous extradural infusion have been measured in few children, 1 7 8 or babies. 8 9 Babies less than 6 months of age have an even greater potential for local anaesthetic toxicity than older children and adults because the free fraction of drug is increased. 10 The increased free fraction probably results from lower concentrations of binding proteins, principally ␣ 1 -acid glycoprotein and albumin. The free fraction decreases inversely with age as the plasma concentration of ␣ 1 -acid glycoprotein increases.
Berde reported from data collected from the members of the Society for Pediatric Anesthesia that seizures can occur in children at plasma concentrations of bupivacaine as low as 2 g ml 91 . 1 Our study showed that some babies accumulate bupivacaine during continuous extradural infusion and can reach plasma concentrations in the range associated with local anaesthetic toxicity in children, despite infusion rates less than the maximum recommended by Berde.
1 This supports the findings of Wolf and colleagues 8 who showed that continuous extradural infusion of bupivacaine in the accepted dose can produce plasma concentrations within the toxic range in children, and Larsson, Olsson and Lönnqvist, 9 who found that babies accumulate bupivacaine during continuous infusions.
Wolf and colleagues measured plasma concentrations of bupivacaine associated with continuous lumbar or thoracic extradural infusions in 20 children aged 2 months to 4 yr. 8 After operation bupivacaine was infused at 0.25-0.375 mg kg 91 h 91 and additional boluses were given, with a maximum dose in any 4 h of 1.6 mg kg
91
. Two children, weighing 10 and 8.3 kg, had concentrations of 2.5 and 3.7 g ml
, respectively, at 24 h. No toxic side effects were reported.
Larsson, Olsson and Lönnqvist 9 measured plasma concentrations of bupivacaine at 6 and 12 h in seven babies aged 0-7 months given a continuous extradural infusion. 9 They injected an initial dose of bupivacaine 1.5-1.9 mg kg 91 with adrenaline and then infused bupivacaine 0.5-0.83 mg kg 91 h 91 without adrenaline. These doses are greater than the maximum recommended. 1 Larsson, Olsson and Lönnqvist 9 found a marked increase in plasma concentrations between 6 and 12 h, demonstrating accumulation of bupivacaine. The mean concentration at 6 h was 1.59 g ml 91 (range 1.2-2.1 g ml 91 ) compared with 2.06 (1.53-2.98) g ml 91 at 12 h. Two babies had central nervous system side effects, probably related to bupivacaine toxicity.
In conclusion, we have shown that babies can accumulate bupivacaine and achieve plasma concentrations above the threshold for toxic side effects, despite infusion rates below the currently accepted maximum. Although we can make no comment on the plasma concentration of unbound bupivacaine in our patients, babies have been shown to have a higher free fraction, at least to the age of 6 months, and a greater potential for toxic side effects. The size of our sample was small but we believe an extradural infusion rate of 0.375 mg kg 91 h 91 is probably an absolute maximum for babies younger than 12 months.
